Recapitulating the immune microenvironment in pediatric brain cancer: preclinical modeling strategies.
Level 5 - mechanism / opinion, no new human data
Narrative review of preclinical model systems with no primary human data
PubMed 41103409 · doi:10.3389/fimmu.2025.1642668
What was done
This review summarizes contemporary and emerging preclinical modeling strategies for pediatric malignant brain tumors, including high-grade glioma and medulloblastoma. It assesses how these models are designed to capture the molecular and histological heterogeneity of tumors and replicate the immunocompetent tumor immune microenvironment.
What was found
The abstract reports no quantitative data or experimental numbers. It notes that conventional preclinical models poorly represent the tumor immune milieu, hindering the translation of immunotherapies, and outlines recent advances in developing immunocompetent animal models that better mirror pediatric brain tumor pathophysiology.
Why it matters
Translating novel immunotherapies into successful clinical trials for pediatric brain tumors requires preclinical testing platforms that faithfully represent tumor-immune interactions. Synthesizing current modeling approaches helps identify more reliable systems for therapeutic screening.
Limits
As a narrative review, it presents no original empirical data, quantitative effect estimates, or systematic study selection methodology. The extent to which these newer preclinical models reliably predict clinical response in pediatric patients remains unestablished in the abstract.